Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B ...

Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.